The B2B platform for the best purchasing descision. Identify and compare relevant B2B manufacturers, suppliers and retailers
Filter
Locations
Result types
Type of company
Select company type
Industries
Select industry
Company status
Select company status preset
Number of employees
Min.
Max.
Founding year
Lock keywords
Exclude keywords
Optional keywords
Gurugram, India
51-100 Employees
2005
Our mission is to continuously make it sure, secure, faster, and cheaper for therapeutic pharmaceutical companies to develop novel solutions. We aspire to accelerate the delivery of new medicines to patients through building partnerships with biotech and pharmaceutical companies around the world. Premas Biotech was founded in 2005 with the vision of transforming drug development. We have acquired in-depth expertise and built state-of-the-art technology platforms to provide quality products that are second to none. By fostering an innovative and inclusive culture, we have created an ecosystem for establishing productive, long-term partnerships with our clients. Prabuddha Kundu is a co-founder and the Managing Director at Premas Biotech. Vivek is a solution architect, always looking to address a problem at its roots and give sustainable and meaningful solutions. As the co-founder and CEO of a startup in Diagnostics product company, NGIVD, Vivek has built an organization from scratch, keeping it bootstrapped as well as raise funds from HNIs and PE firms.
+
Featured
CELL LINE DEVELOPMENT - Services - Premas Biotech
... CELL LINE DEVELOPMENT - Services - Premas ...
Plan-les-Ouates, Switzerland
11-50 Employees
2001
We believe in developing each individual to their full potential. Our team, distributed throughout the US and Europe, is committed to a high standard of quality and execution. Built upon a foundation of world-class analytical capabilities, we deliver efficient process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs. Offering clinical biologics manufacturing services for therapeutics and vaccines. Reliable GMP manufacturing services for commercial supply of biotherapeutics. Coli expression for clean, efficient therapeutic protein production. Raising the bar on microbial expression and manufacturability.
+
Featured
Microbial Cell Line Development
... Microbial Cell Line Development - KBI ...
Monthey, Switzerland
11-50 Employees
2001
We are a Swiss biologics CDMO (contract development and manufacturing organization) specializing in challenging protein expression services and based in Monthey, Switzerland. The heart of ExcellGene is applying smart science and technology to provide high quality proteins.We serve life science companies that need to move rapidly and confidently from concept and discovery to clinical use. ExcellGene is privately owned, was founded in 2001 by Prof. Divor Kiseljak joined ExcellGene in 2012 as a Process Scientist to further the Company’s expertise in transient gene expression in mammalian cells. Before joining ExcellGene SA and co-founding JMO Advisory and Associates Sarl, Martin developed and implemented tailored solutions in the fields of strategic planning, finance, project- and change-management as well as quality improvement audits in startup companies. Both founders are often invited to speak at conferences on the manufacturing of proteins with recombinant cells in bioreactors. Our twin expertise in biology and engineering enables us to successfully conclude the most challenging protein expressions and virus vector productions. Communication has to be easy and transparent, and the delivery of our product has to be in purity and quantity as needed, so that the timing for starting a clinical trial matches our plans.
+
Featured
Cell line development services
... CHO & HEK cell line development services and process optimization. Stable cell lines in 5 months, at 8x higher titer than industry standard. ...
Freiburg im Breisgau, Germany
11-50 Employees
2014
CYTENA is a multiple award-winning biotechnology company providing cutting-edge single-cell dispensers, microplate washers, liquid handlers, and live-cell analyzers to scientists and researchers at the world’s top institutions. Our products aim to reduce theorgan shortage and speed up drug development byproviding accessible life science solutions that combine biology and technology, fundamentally shifting the global healthcare industry. Founded in 2014 and headquartered in Freiburg, Germany, CYTENA became part of the BICO bio-convergence revolution in 2019, joining 1000+ colleagues and 13 companies offering a portfolio of technologies, products, and services to create the future of medicine. Twitter Facebook Linkedin Envelope Post This CYTENA Launches The 2nd Generation UP.SIGHT And C.STUDIO – An All-in-one Solution for Industrial Cell Line Development Revolutionizing the.
+
Featured
Automated Cell Line Development
... Boost your lab's productivity with cutting-edge stable cell line development instruments. Automated workflows guarantee speed, precision, accuracy, and reliability for your research. ...
Bengaluru, India
1-10 Employees
Shilps Dexter TM Platform is uniquely suited for getting you the rare cells you want. Finding the rights cells is like looking for a needle in a haystack. For cell based pharmaceuticals, whether its cell therapies or biopharmaceuticals, getting the right cell is crucial. Our patented platform enables massively parallel functional interrogation of thousands of single cells - so that biologists can do what they are best at doing. We find the rare cells that work for novel therapeutics .
+
Featured
Cell Line Development
... Cell Line Development ...
Fremont, United States
11-50 Employees
2014
Biologics CDMO services from DNA to Drug Product from a team of experts 100% committed to your success. Bionova initiates expansion project to quadruple GMP biologics manufacturing capacity. Bionova is a biologics CDMO focused on the development and production of mAbs and other therapeutic proteins using mammalian cell culture processes. With technical depth you’d expect from a larger biologics CDMO, our team offers a flexible, fast, client-first culture that our clients find refreshing.
+
Featured
Cell Line Development
... Bionova's mammalian cell line development optimally deploys DNA sequences into working cell lines to deliver quality, productivity and speed. ...
Freiburg im Breisgau, Germany
11-50 Employees
1999
We provide a safe workplace as well as continuous training and respect of privacy for every staff member. This allows the partners to focus on the respective indication. With our moss-based platform, we are going to translate the features of this ancient plant into the therapies of tomorrow. Björn has 27 years of experience in academia and industry. Karin has gained a broad clinical expertise in orphan diseases working for companies such as Novartis, Genzyme, BioMarin and Horizon Pharmaceuticals. Quality is the prime goal throughout the company. We know you would love being part of a highly motivated team passionate about making unprecedented therapies available to patients. As a serial entrepreneur, Henrik co-founded several life science start-ups including Symbiotec, Nanomi, and Activaero and supported their growth leading to several trade sales.
+
Featured
Everything you expect from cell line development – yet without the problems
... Everything you expect from cell line development – yet without the problems. Tailored glycosylation, flexible genetic engineering, pathogen-free processing and fusion toxin production. ...
Cologne, Germany
11-50 Employees
2003
We developed a workflow to increase the number of productive clones. Cytiva has acquired CEVEC Pharmaceuticals, a leading German provider of high-performance cell line development and viral vector manufacturing technologies. Cytiva now offers ELEVECTA™ producer cell line, which contains all genes stably integrated to produce AAV. An innovative technology ensuring scalability to treat hundreds of thousands. Developing a cell line is a critical first step in your therapeutic journey. Whether you’re producing proteins or viral vectors, you’ll need high productivity, consistency, and reproducibility to meet regulatory guidelines and achieve commercial success.
+
Featured
CELL LINE DEVELOPMENT FOR THE EXPRESSION OF GLYCO-OPTIMIZED PROTEINS
... CELL LINE DEVELOPMENT FOR THE EXPRESSION OF GLYCO-OPTIMIZED ...
Southborough, United States
11-50 Employees
2014
As a contract development and manufacturing organization (CDMO), Boston Institute of Biotechnology, LLC, provides full spectrum services for microbial fermentation and mammalian cell culture processes. Our facility in Southborough MA, within the Genetown Hotbed of Metro-Boston Area, offers flexible and adaptable lab spaces designed to meet the needs of our clients. It takes a lot to be one of the most trusted CDMO partners. Decades of working experience in world-leading CDMOs make our team one of the best choices for your CMC needs.
+
Featured
Cell Line Development | Boston Institution of Biotechnology
... At BIB, we can provide cell line development services for you. Based on our extensive working experience, we can help you develop your ideal microbial cells. ...
London, United Kingdom
11-50 Employees
2001
Abzena is as committed to success as you are. Abzena for everyone; bring your whole self to work. We are committed to creating workplaces that reflect the communities we serve so that everyone feels empowered. At Abzena, we place the highest value on our environmental, health, and safety programs. As Abzena continues to grow and provide essential CDMO services to our partners and their patients, we embrace the opportunity to become an industry leader in corporate sustainability. Abzena’s Quality organization provides safe and compliant products to your patients. Abzena develops and implements fully integrated and tailored, innovative solutions that make it possible for you to realize the full potential of your molecule. Built to accelerate the development of your novel treatments.
+
Featured
Biologic Cell Line Development
... Abzena are experts in cell line development for biosimilars as well as research cell banking for the highest quality molecules, reliably delivered. ...
Technologies which have been searched by others and may be interesting for you:
Some interesting numbers and facts about the results you have just received for Cell Line Development
| Country with most fitting companies | United States |
| Amount of fitting manufacturers | 69 |
| Amount of suitable service providers | 60 |
| Average amount of employees | 11-50 |
| Oldest suiting company | 1999 |
| Youngest suiting company | 2014 |
Cell line development is a sophisticated biotechnological process that involves the selection, adaptation, and propagation of specific cells in vitro to establish a stable, homogeneous cell population that can express a target protein or compound consistently. This foundational technique is pivotal in various scientific and medical research fields, including drug discovery, vaccine production, and the development of therapeutic antibodies. By utilizing genetic engineering, cells—often mammalian—are manipulated to produce high yields of proteins, which are then harvested for pharmaceutical applications. The process begins with the transfection of a chosen host cell with the desired genetic material, followed by rigorous screening and selection to isolate those cells exhibiting optimal expression levels of the target molecule. These selected cells are then cultured under controlled conditions to ensure genetic stability and productivity over time. The significance of cell line development lies not only in its ability to accelerate the pace of medical research and pharmaceutical development but also in its contribution to the understanding of complex biological processes and disease mechanisms. As such, it plays a crucial role in the biotechnological industry, where the demand for high-quality, reproducible cell lines is essential for the advancement of therapeutic innovations and the efficient production of biologics, underscoring its vital impact on public health and personalized medicine.
1. Higher Efficiency
Cell line development offers a significantly higher level of efficiency compared to traditional methods. By utilizing immortalized cells, researchers can conduct experiments with a consistent cell population, reducing variability and enhancing the reliability of experimental results. This consistency is crucial for high-throughput screening and for the production of biologics, where uniformity is key.
2. Cost-Effectiveness
The process is notably cost-effective, primarily because cell lines can be used repeatedly over an extended period. This reusability reduces the need for frequent sample collection from primary sources, which can be both time-consuming and expensive. Moreover, the scalability of cell line development allows for the production of large quantities of biological materials, such as proteins or antibodies, at a lower cost.
3. Enhanced Reproducibility
Cell line development ensures enhanced reproducibility of research findings. Since cell lines can be genetically modified and cloned, researchers can work with identical copies of the cell line across different experiments and even share these with other laboratories, ensuring that findings can be reliably replicated and validated.
4. Genetic Manipulation
The ability to genetically manipulate cell lines provides a significant advantage. It allows for the introduction or silencing of genes to study their effects on cell behavior, disease progression, or drug response. This capability is crucial for gene therapy research, drug development, and the study of complex genetic diseases.
While evaluating the different suppliers make sure to check the following criteria:
1. Expertise and Experience
Ensure the supplier has extensive experience in cell line development, with a portfolio showcasing successful projects in your specific area of interest.
2. Quality Assurance
Verify that the supplier follows stringent quality control processes, adhering to international standards such as ISO or GMP to ensure the integrity and reliability of the cell lines.
3. Technological Capability
Assess the technological tools and platforms the supplier uses. Advanced genetic engineering and cell culture technologies are essential for efficient and high-quality cell line development.
4. Customization and Flexibility
The supplier should offer customizable solutions that can be tailored to meet your specific project requirements, demonstrating flexibility in their approach to cell line development.
5. Time and Cost Efficiency
Consider suppliers who can deliver high-quality cell lines within reasonable timelines and budgets, ensuring your project remains on track and within financial constraints.
6. Customer Support and Communication
Choose a supplier that provides excellent communication and customer support, offering technical assistance and updates throughout the cell line development process.
Cell line development plays a crucial role in the pharmaceutical industry, primarily for drug discovery and development processes. Companies utilize specific cell lines as models to study the effects of new drugs, ensuring safety and efficacy before proceeding to clinical trials. This method offers a cost-effective and reliable means of screening compounds, thereby accelerating the development timeline of new therapeutics. In the biotechnology sector, cell line development is essential for producing biologics, including vaccines, antibodies, and other therapeutic proteins. By engineering cell lines to produce these biologics, companies can achieve high yield and purity, which is vital for meeting the rigorous standards of regulatory agencies. This application not only supports the production of existing treatments but also facilitates the research and development of innovative biologic therapies. The cosmetic industry also leverages cell line development for testing product safety and efficacy without relying on animal testing. By using human-derived cell lines, companies can evaluate how cosmetic products interact with human cells, ensuring they are safe for consumer use. This approach aligns with increasing regulatory and consumer demand for cruelty-free products, offering a sustainable and ethical alternative to traditional testing methods. Agriculture companies utilize cell line development for genetic engineering purposes, aiming to enhance crop traits such as yield, nutritional value, and resistance to pests and diseases. By manipulating specific genes within plant cell lines, researchers can create modified crops that address global food security challenges while reducing the need for chemical pesticides, thereby promoting sustainable agricultural practices.
Cell line development, a cornerstone technique in biotechnology and pharmaceutical industries, has reached a high Technology Readiness Level (TRL), typically positioned between TRL 7 to TRL 9. This advanced TRL signifies that the methodologies involved in cell line development have undergone extensive validation in real-world settings, demonstrating their efficacy and reliability for large-scale applications. The progression to such a high TRL can be attributed to several technical advancements and rigorous validation processes. Innovations in genetic engineering, for instance, have enabled precise modifications of cellular DNA, leading to enhanced cell lines with desirable traits such as increased protein production, stability, and disease resistance. Additionally, advancements in culturing techniques have improved the scalability and efficiency of cell line development, facilitating their application in producing biologics, including vaccines, antibodies, and therapeutic proteins. The integration of high-throughput screening and automation has further streamlined the selection and optimization of high-performing cell lines, reducing development time and cost. Collectively, these technical achievements underpin the high TRL of cell line development, reflecting its readiness and widespread adoption in producing complex biological products.
In the short-term phase of cell line development, we anticipate significant advancements in automation and precision editing tools. The introduction of CRISPR-Cas9 gene editing has revolutionized the field, and its applications are expected to expand, allowing for quicker and more accurate genetic modifications. This period will also see the rise of automated cell culture systems, which will reduce human error and increase the efficiency of cell line development processes. Moving into the mid-term, the focus shifts towards the integration of artificial intelligence (AI) and machine learning (ML) in optimizing cell line development. These technologies will enable predictive modeling of cell line behaviors, facilitating the selection of high-yield and stable cell lines. Additionally, we will witness the development of more sophisticated bioreactors, capable of simulating various environmental conditions to enhance cell line productivity and scalability. In the long-term, the horizon of cell line development is set to be transformed by the advent of synthetic biology. The creation of entirely synthetic cell lines tailored for specific therapeutic productions is on the cards. This groundbreaking shift will not only increase the robustness and yield of cell lines but also significantly reduce the ethical concerns surrounding the use of animal and human cells. Moreover, the long-term phase will likely see cell lines capable of producing complex biologics, including multispecific antibodies and intricate protein structures, that are currently challenging to manufacture.
